Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer

Inclusion Criteria: * Histologically or cytologically confirmed unresectable advanced gastric or gastroesophageal junction cancer; * No previous chemotherapy and radiation for advanced disease except palliative radiation for a local pain control; * At least one evaluable lesion per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1; * ECOG (Eastern Cooperative Oncology Group) performance status 0-1; * Recovery from the toxicities of previous therapy; * Adequate bone marrow and organ function. Hb≥8 G/L; Absolute neutrophil ≥ 2.0 G/L; PLT ≥100 G/L ;ALT/AST ≤1.5 ULN or ≤5ULN with liver metastases; TBIL ≤1.5 ULN; Cr≤1.0 ULN; * Life expectancy ≥3 months; * For men and women of childbearing potential, agree on taking effective contraceptive method of birth control from the signed informed consent until 3 months after the last study drug administration; * Signed informed consent. Exclusion Criteria: * Pathology type other than adenocarcinoma,such as squamous cell carcinoma; * Previous treatment with taxanes, cisplatin or S-1; * Relapse within 6 months after the end of adjuvant chemotherapy; * Known brain metastases; * Complete or incomplete intestinal obstruction or uncontrolled gastrointestinal bleeding; * Known deficiency of DPD enzyme; * Kown HIV infecton or drug addiction; * Any acute or chronic medical or psychiatric condition that would make the patient inappropriate for entry into this trial in the judgement of investigators; * Myocardial infarction within 6 months prior to the entry of this trial; * Known history of allergic reaction to taxanes and platinum; * Pregnant or breast feeding women.